EUVIMEDEUVIMED entdecken
Crossref

Laboratory approach for vaccine‐induced thrombotic thrombocytopenia diagnosis in the Netherlands

Romy T Meier, Leendert Porcelijn, Suzanne Hofstede-van Egmond, Yvonne M C Henskens, Jonathan M Coutinho, Marieke J H A Kruip, An K Stroobants, Jaap J Zwaginga, Johanna G van der Bom, C Ellen van der Schoot iD, Masja de Haas iD, Rick Kapur iD

Vox Sanguinis · 2024

DOI: 10.1111/vox.13633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Romy T Meier und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Neth…. Hauptthemen laut MEDLINE: Platelet Factor 4, Thrombocytopenia, Thrombosis, COVID-19 Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Sanquin PPOC22-14/L2714 (to Rick Kapur).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Vaccine‐induced thrombotic thrombocytopenia (VITT) is a rare adverse effect characterized by thrombocytopenia and thrombosis occurring after COVID‐19 vaccination. VITT pathophysiology is not fully unravelled but shows similarities to heparin‐induced thrombocytopenia (HIT). HIT is characterized by the presence of antibodies against platelet factor 4 (PF4)/heparin complex, which can activate platelets in an FcγRIIa‐dependent manner, whereas IgG‐antibodies directed against PF4 play an important role in VITT. Materials and Methods We characterized all clinically suspected VITT cases in the Netherlands from a diagnostic perspective and hypothesized that patients who developed both thrombocytopenia and thrombosis display underlying mechanisms similar to those in HIT. We conducted an anti‐PF4 ELISA and a functional PF4‐induced platelet activation assay (PIPAA) with and without blocking the platelet‐FcγRIIa and found positivity in both tests, suggesting VITT with mechanisms similar to those in VITT.

Results

We identified 65 patients with both thrombocytopenia and thrombosis among 275 clinically suspected VITT cases. Of these 65 patients, 14 (22%) tested positive for anti‐PF4 and PF4‐dependent platelet activation. The essential role of platelet‐FcγRIIa in VITT with mechanisms similar to those in HIT was evident, as platelet activation was inhibited by an FcγRIIa‐blocking antibody in all 14 patients.

Conclusion

Our study shows that only a small proportion of clinically suspected VITT patients with thrombocytopenia and thrombosis have anti‐PF4‐inducing, FcɣRIIa‐dependent platelet activation, suggesting an HIT‐like pathophysiology. This leaves the possibility for the presence of another type of pathophysiology (‘non‐HIT like’) leading to VITT. More research on pathophysiology is warranted to improve the diagnostic algorithm and to identify novel therapeutic and preventive strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Factor 4ThrombocytopeniaThrombosisCOVID-19 VaccinesReceptors, IgGPlatelet ActivationHumansNetherlandsFemaleMaleMiddle AgedAdultAgedCOVID-19HeparinBlood PlateletsImmunoglobulin G

Stichwörter der Autor:innen

COVID‐19platelet factor 4thrombocytopeniathrombosisvaccination

Substanzen

Platelet Factor 4COVID-19 VaccinesReceptors, IgGPF4 protein, humanFc gamma receptor IIAHeparinImmunoglobulin G

Autor:innen und Institutionen

  • Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Sanquin, The Netherlands.
  • Central Diagnostic Laboratory, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Department of Neurology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Department of Haematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Clinical Chemistry, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: C Ellen van der Schoot, Masja de Haas, Rick Kapur

Förderung

  • Sanquin PPOC22-14/L2714 (to Rick Kapur)

Zitieren

APA

Meier, R. T., Porcelijn, L., Hofstede-van Egmond, S., Henskens, Y. M. C., Coutinho, J. M., Kruip, M. J. H. A., Stroobants, A. K., Zwaginga, J. J., van der Bom, J. G., van der Schoot, C. E., de Haas, M., & Kapur, R. (2024). Laboratory approach for vaccine‐induced thrombotic thrombocytopenia diagnosis in the Netherlands. Vox Sanguinis. https://doi.org/10.1111/vox.13633

Vancouver

Meier RT, Porcelijn L, Hofstede-van Egmond S, Henskens YMC, Coutinho JM, Kruip MJHA, et al. Laboratory approach for vaccine‐induced thrombotic thrombocytopenia diagnosis in the Netherlands. Vox Sanguinis. 2024. doi:10.1111/vox.13633

BibTeX
@article{Meier2024,
  author = {Meier, Romy T and Porcelijn, Leendert and Hofstede-van Egmond, Suzanne and Henskens, Yvonne M C and Coutinho, Jonathan M and Kruip, Marieke J H A and Stroobants, An K and Zwaginga, Jaap J and van der Bom, Johanna G and van der Schoot, C Ellen and de Haas, Masja and Kapur, Rick},
  title = {Laboratory approach for vaccine‐induced thrombotic thrombocytopenia diagnosis in the Netherlands},
  journal = {Vox Sanguinis},
  year = {2024},
  doi = {10.1111/vox.13633}
}
Kostenlos starten →